Europe Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User
상품코드:1597065
리서치사:The Insight Partners
발행일:2024년 10월
페이지 정보:영문 87 Pages
라이선스 & 가격 (부가세 별도)
한글목차
유럽의 약동학 서비스 시장은 2023년에 2억 2,216만 달러로 평가되었고, 2031년에는 3억 8,738만 달러에 이를 것으로 예측되며, 2023년부터 2031년까지의 CAGR은 7.2%로 추정됩니다.
CRO에 대한 약동학 서비스 아웃소싱이 유럽 약동학 서비스 시장을 견인
CRO(의약품 개발 업무 수탁기관)에 대한 약동학 서비스의 아웃소싱은 의약품 제조업체나 스폰서에게 몇가지 이점을 제공합니다. 또한 신속한 턴어라운드 시간 달성 동시에 유연한 작업과 핵심 업무에 대한 확장성에 집중할 수 있습니다. 약수처리 과정은 복잡하며 오류와 잘못된 결과가있는 경우 상당한 비용과 프로세스 지연으로 이어집니다. CRO는 약물 동태학과 같은 전문 지식을 가진 숙련된 과학자와 연구자를 고용합니다. 액세스를 제공함으로써 그러한 숙련된 인력을 고용하고 인적 자원을 육성하기위한 추가 트레이 그러므로 유망한 신약 후보가 있지만 자원이 한정되어 있는 소규모 기업이나 사업의 다각화에 임하고 있는 대기업은 조직화된 CRO가 제공하는 임상 연구 서비스를 선택하고 유럽의 약동학 서비스 시장을 강화하고 있습니다.
유럽 약동학 서비스 시장 개요
유럽 약동학 서비스 시장은 독일, 프랑스, 영국, 스페인, 이탈리아 및 기타 유럽으로 구분됩니다. 독일과 이탈리아 등의 국가들은 이 지역 시장에서 큰 공헌자 점유율을 차지할 것으로 예상되며, 프랑스, 영국, 스페인 등의 국가들은 약물동태 서비스의 성장 기회를 가질 것으로 보입니다. 유럽의 약동학 서비스 시장은 신약 개발을 위한 임상시험수 증가와 약물동태의 변동을 이해하기 위한 in-vivo 및 in-vitro 모델의 채용 증가로 향후 수년간 성장할 것으로 예상 합니다.
유럽 약동학 서비스 시장의 수익과 2031년까지의 예측(단위: 100만 달러)
유럽 약동학 서비스 시장 세분화
유럽의 약동학 서비스 시장은 약물 유형별, 서비스 유형별, 치료 용도별, 최종 사용자별, 국가별로 분류됩니다.
약물 유형별로 유럽의 약동학 서비스 시장은 저분자, 고분자 및 백신으로 구분됩니다. 저분자 부문은 2023년에 가장 큰 시장 점유율을 차지했습니다.
서비스 유형별로 유럽의 약동학 서비스 시장은 전임상 ADME 및 인간 시험, PK/PD 분석 및 보고, 투여 시뮬레이션, 위험 분석 등으로 분류됩니다. 2023년에는 전임상 ADME와 인간 시험 부문이 가장 큰 시장 점유율을 차지했습니다.
치료 용도별로 유럽의 약동학 서비스 시장은 암, 감염증, 신경질환, 자가면역질환, 부인과질환, 심혈관질환, 호흡기질환 등으로 구분됩니다. 2023년에는 암 영역이 가장 큰 시장 점유율을 차지하고 있습니다.
최종 사용자별로 유럽의 약동학 서비스 시장은 제약·바이오테크놀러지 기업, CRO, 기타로 구분됩니다. 2023년에는 CRO가 가장 큰 시장 점유율을 차지했습니다.
국가별로 유럽의 약동학 서비스 시장은 독일, 프랑스, 영국, 이탈리아, 스페인 및 기타 유럽으로 구분됩니다.
Charles River Laboratories International Inc, Eurofins Scientific SE, Evotec SE, Certara Inc, Parexel International Corp, Thermo Fisher Scientific Inc, Allucent, PACIFIC BIOLABS, SGS SA 등이 유럽의 약동학 서비스 시장에서 사업을 전개하는 주요 기업입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 유럽의 약동학 서비스 시장 : 주요 시장 역학
시장 성장 촉진요인
만성 질환·감염증의 유병률의 상승
약동학 연구에의 응용 범위의 확대
CRO에 대한 약동학 서비스의 아웃소싱
시장 성장 억제요인
신흥국에서의 약동학 서비스 업자의 리치의 제약
시장 기회
약물동태의 편차를 이해하기 위한 생체내·생체외 모델의 채용 증가
향후의 동향
약동학 서비스에서 빅데이터 분석 채용 증가
성장 촉진요인과 저해요인의 영향
제5장 유럽의 약동학 서비스 시장 분석
유럽의 약동학 서비스 시장의 수익(2021-2031년)
제6장 유럽의 약동학 서비스 시장 분석 : 약제 유형별
저분자
대형 분자
백신
제7장 유럽의 약동학 서비스 시장 분석 : 서비스 유형별
전임상 ADME 및 인간 시험
PK/PD 분석과 리포팅
투여 시뮬레이션
리스크 분석
기타
제8장 유럽의 약동학 서비스 시장 분석 : 치료 용도별
암 영역
감염증
신경질환
자가면역질환
부인과 질환
순환기 질환
호흡기 질환
기타
제9장 유럽의 약동학 서비스 시장 분석 : 최종 사용자별
제약·바이오테크놀러지 기업
CRO(의약품 개발 업무 수탁 기관)
기타
제10장 유럽의 약동학 서비스 시장 : 국가별 분석
유럽
독일
프랑스
영국
이탈리아
스페인
기타
제11장 기업 프로파일
Charles River Laboratories International Inc
Eurofins Scientific SE
Evotec SE
Certara Inc.
Parexel International Corp
Thermo Fisher Scientific Inc.
Allucent
PACIFIC BIOLABS
SGS SA
제12장 부록
JHS
영문 목차
영문목차
The Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031; it is estimated to register a CAGR of 7.2% from 2023 to 2031.
Outsourcing of Pharmacokinetics Services to CROs Drives Europe Pharmacokinetics Services Market
Outsourcing pharmacokinetics services to contract research organizations (CROs) offers several advantages to drug manufacturers and sponsors. They can operate cost-effectively by opting for these services. Moreover, they can focus on working flexibly and bringing scalability to their core operations, alongside achieving fast turnaround time. Outsourcing helps pharmaceutical companies to focus on product commercialization while implementing measures for capacity building, cost reduction, and data management. The drug discovery process is complex, and any error or false result can lead to significant costs and delay the process. CROs employ experienced scientists and researchers who hold expertise in pharmacokinetics and other fields. Thus, they provide pharma companies with access to their expertise, thereby eliminating the need to invest in hiring such skilled workforces or providing extra training to build them. Therefore, small companies with promising drug candidates but limited resources and large companies involved in diversifying their operations are opting for clinical research services provided by well-organized CROs, which bolsters the Europe pharmacokinetics services market.
Europe Pharmacokinetics Services Market Overview
The Europe pharmacokinetics services market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account significant contributors share of the market in the region, and countries such as France, the UK, and Spain are likely to have growth opportunities for pharmacokinetics services. The European pharmacokinetics services market is expected to grow in the coming years with the rising number of clinical trials for new drug development, and the increasing adoption of in-vivo and in-vitro models for understanding pharmacokinetics variability.
Europe Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)
Europe Pharmacokinetics Services Market Segmentation
The Europe pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.
Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.
In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.
By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.
By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.
By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. France dominated the Europe pharmacokinetics services market share in 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the Europe pharmacokinetics services market.
Table Of Contents
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Europe Analysis
5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Europe Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Europe Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Europe Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Europe Pharmacokinetics Services Market - Country Analysis
10.1 Europe
10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Evotec SE
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Certara Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.5 Parexel International Corp
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Thermo Fisher Scientific Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Allucent
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 PACIFIC BIOLABS
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 SGS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
